Duncan-Williams

Duncan-Williams is out with a research report on Noble Corporation (NYSE: NE) and it has a Strong Buy rating and a $57.25 price target on shares. In a note to clients, Duncan-Williams writes, "Backlog stands at $13 billion as of June 30, 2011. The fleet is 73 percent booked for the remainder of...

Duncan Williams has downgraded Wright Medical Group (NASDAQ: WMGI) from Buy to Hold and maintains its $18.50 price target.

Duncan-Williams is out with its report today on Ensco (NYSE: ESV), reiterating Strong Buy. In its report, Duncan-Williams writes, "Our new 2011 earnings estimate is $3.30 per share down from $3.40 per share. Our 2012 earnings estimate remains $5.90 per share. We reiterate our STRONG BUY rating and...

Duncan Williams has published a research report on Forest Laboratories (NYSE: FRX) after the Icahn crisis. In the report, Forest Laboratories wrote, "Forest successfully thrwarted Icahn's attempts to install directors on its board and we think the experience has strengthened the company. During...

Duncan-Williams is out with its report today on Kensey Nash (NASDAQ: KNSY), raising its PT to $32 from $31. In its report, Duncan-Williams writes, "We are maintaining our BUY rating and are raising our twelve month price target to $32.00 from $31.00. This represents approximately 17 times our...

Duncan Williams has raised the price target on Vascular Solutions (NASDAQ: VASC) from $15 to $17 and maintains its Buy rating.

Duncan-Williams is out with its report today on eResearch Technology (NASDAQ: ERT), lowering its PT from $8.50 to $8.00. In its report, Duncan-Williams writes, "We are maintaining a BUY rating and are lowering our twelve month price target to $8.00 from $8.50. This represents approximately 20...

Duncan-Williams has published a research report on Vascular Solutions (NASDAQ: VASC) previewing earnings for the second quarter. In the report, Duncan-Williams wrote, "Our Q2:11 Catheters revenue estimate is $13.5 million. This represents approximately 31% growth compared to the same period last...

Duncan-Williams has published a research report on Wright Medical Group (NASDAQ: WMGI) commenting on the 2Q11 release of earnings results. In the report, Duncan-Williams wrote, "WMGI reported Q2:11 revenue and adjusted EPS of $132.5 million and $0.23, below our revenue estimate of $134.9 million...

Duncan Williams has raised the price target on Forest Laboratories (NYSE: FRX) from $45 to $48 and maintains its Buy rating.

Duncan-Williams, which upgraded shares of Salix Pharmaceuticals (NASDAQ: SLXP), is providing some color on the stock. “We use DCF analysis (11.5% WACC, down from 12.5% previously, and a 1% terminal growth rate) to arrive at our price target,” Duncan-Williams writes. “We believe the IBS situation...

Duncan-Williams has a Buy rating and a $51 price target on shares of Endo Pharmaceuticals Holdings, Inc. (NASDAQ: ENDP). In a note to clients, Duncan-Williams writes, "We updated our model to include 3Q11 and 13 days of AMS sales in June. We also converted our therapeutic models from IMS to...

Duncan-Williams is maintaining its Hold rating on shares of Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX). “Our valuation is now primarily based on a DCF analysis,” Duncan-Williams writes. “We use a WACC of 14% with a terminal growth rate of 0% to arrive at a hypothetical estimate of $6.00 (...